Cargando…
Is pricing of dolutegravir equitable? A comparative analysis of price and country income level in 52 countries
OBJECTIVES: Differences in marketed prices of antiretrovirals raises questions about the fairness of pricing medicines of significant public health importance such as dolutegravir (DTG). In view of the reduced prices of generically available efavirenz (EFV), there is a need to determine if previous...
Autores principales: | Sim, Joel, Hill, Andrew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mediscript Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6248837/ https://www.ncbi.nlm.nih.gov/pubmed/30515303 |
Ejemplares similares
-
Analysis of prices paid by low-income countries - how price sensitive is government demand for medicines?
por: Srivastava, Divya, et al.
Publicado: (2014) -
Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries
por: Hill, Andrew, et al.
Publicado: (2015) -
Insulin prices, availability and affordability in 13 low-income and middle-income countries
por: Ewen, Margaret, et al.
Publicado: (2019) -
Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries
por: Barber, Melissa J., et al.
Publicado: (2020) -
Impact of External Price Referencing on Medicine Prices – A Price Comparison Among 14 European Countries
por: Leopold, Christine, et al.
Publicado: (2012)